,node_1,node_2,edge,chunk_id
0,material properties,mechanical properties,Mechanical properties are a subset of material properties that describe how materials respond to forces.,727aa210b89e4832ba3eb1c54223513e
1,material properties,thermal properties,Thermal properties are another subset of material properties that indicate how materials conduct heat.,727aa210b89e4832ba3eb1c54223513e
2,material properties,electrical properties,Electrical properties define how materials conduct electricity and are part of the broader category of material properties.,727aa210b89e4832ba3eb1c54223513e
3,materials science,material characterization,Material characterization is a key process in materials science for understanding the properties and structure of materials.,727aa210b89e4832ba3eb1c54223513e
4,materials science,materials engineering,Materials engineering applies principles of materials science to design and develop new materials.,727aa210b89e4832ba3eb1c54223513e
5,materials science,metallurgy,Metallurgy is a subfield of materials science focused on the properties and applications of metals.,10afa8d0b52143648c29e82dd9311a71
6,materials science,polymer science,"Polymer Science is a subfield of materials science that studies the synthesis, characterization, and applications of polymers.",10afa8d0b52143648c29e82dd9311a71
7,materials science,ceramics,"Ceramics is a branch of materials science that deals with the study of inorganic, non-metallic materials.",10afa8d0b52143648c29e82dd9311a71
8,materials science,nanomaterials,"Nanomaterials are materials with structural components smaller than 100 nanometers, studied within materials science.",10afa8d0b52143648c29e82dd9311a71
9,materials science,composite materials,Composite Materials are made from two or more constituent materials with significantly different physical or chemical properties.,10afa8d0b52143648c29e82dd9311a71
10,assay pipeline,preclinical discovery,is used for,3946a6404b2b4560a27cd78b8474a899
11,glucocerebrosidase modulators,assay pipeline,is the focus of,3946a6404b2b4560a27cd78b8474a899
12,compound libraries,bioactive compounds,are enriched with,3946a6404b2b4560a27cd78b8474a899
13,bioactive compounds,mechanisms of action,have,3946a6404b2b4560a27cd78b8474a899
14,screening process,small molecules,identified,3946a6404b2b4560a27cd78b8474a899
15,small molecules,glucocerebrosidase,are relevant to,3946a6404b2b4560a27cd78b8474a899
16,target atlas,molecular targets,provides,3946a6404b2b4560a27cd78b8474a899
17,molecular targets,gba1 pathway,regulate,3946a6404b2b4560a27cd78b8474a899
18,output set,potential therapeutics,produced a,3946a6404b2b4560a27cd78b8474a899
19,potential therapeutics,glucocerebrosidase modulators,may include,3946a6404b2b4560a27cd78b8474a899
20,gaucher disease,glucocerebrosidase,is caused by deficiency of,e6c37fd7b9734096b7a545e2dc728b2b
21,glucocerebrosidase,gba1 gene,is encoded by gene,e6c37fd7b9734096b7a545e2dc728b2b
22,gba1 gene,biallelic loss-of-function mutations,is affected by,e6c37fd7b9734096b7a545e2dc728b2b
23,gba1 gene,parkinson's disease,is a genetic risk factor for,e6c37fd7b9734096b7a545e2dc728b2b
24,small-molecule stabilizers,glucocerebrosidase,are developed for,e6c37fd7b9734096b7a545e2dc728b2b
25,discovery and optimization,lead compounds,is limited by,e6c37fd7b9734096b7a545e2dc728b2b
26,cell-based assays,high-throughput screening,are amenable to,e6c37fd7b9734096b7a545e2dc728b2b
27,gaucher disease,related disorders,is related to,e6c37fd7b9734096b7a545e2dc728b2b
28,robust cell-based assays,lead compounds,facilitate discovery of,e6c37fd7b9734096b7a545e2dc728b2b
29,mutations,gaucher disease,cause,e6c37fd7b9734096b7a545e2dc728b2b
30,glucocerebrosidase (gcase),gaucher disease,is implicated in,9739d55bef1f4e19b77d1fc84bdb9f7f
31,glucocerebrosidase (gcase),parkinson's disease,is implicated in,9739d55bef1f4e19b77d1fc84bdb9f7f
32,l444p variant of gcase,pathogenic variant,is a type of,9739d55bef1f4e19b77d1fc84bdb9f7f
33,gcase,protein misfolding,causes,9739d55bef1f4e19b77d1fc84bdb9f7f
34,gcase,trafficking obstruction,causes,9739d55bef1f4e19b77d1fc84bdb9f7f
35,therapeutic target,gcase,is,9739d55bef1f4e19b77d1fc84bdb9f7f
36,high-throughput assays,cell-based assays,are a type of,9739d55bef1f4e19b77d1fc84bdb9f7f
37,gcase,hibit peptide reporter tag,is labeled with,9739d55bef1f4e19b77d1fc84bdb9f7f
38,quantitative assays,correctors of protein misfolding,identify,9739d55bef1f4e19b77d1fc84bdb9f7f
39,gaucher disease,monogenic disorder,is a type of,9739d55bef1f4e19b77d1fc84bdb9f7f
40,protein stabilization,cellular systems,enables quantitation in,e35825b1f65f4127a808fcf0ef92d448
41,talen gene editing,hibit-gba1 transgene,allows stable integration of,e35825b1f65f4127a808fcf0ef92d448
42,hibit-gba1 transgene,intragenic safe-harbor locus,is integrated into,e35825b1f65f4127a808fcf0ef92d448
43,gba1-knockout h4 cells,gaucher disease cell model,is a type of,e35825b1f65f4127a808fcf0ef92d448
44,gaucher disease cell model,lead discovery,is amenable to,e35825b1f65f4127a808fcf0ef92d448
45,titration-based quantitative high-throughput screening,lead discovery,is a method for,e35825b1f65f4127a808fcf0ef92d448
46,lead optimization,structureâ€“activity relationships,is achieved via,e35825b1f65f4127a808fcf0ef92d448
47,primary screening,"10,779 compounds",involves,e35825b1f65f4127a808fcf0ef92d448
48,ncats bioactive compounds,chemical libraries,is a source of,e35825b1f65f4127a808fcf0ef92d448
49,cellular systems,target biology,maintains,e35825b1f65f4127a808fcf0ef92d448
50,hibit-gcase-l444p,stabilizers,is stabilized by,ba3bf95efaea4452975aea144a764402
51,ambroxol,pharmacological chaperones,is a type of,ba3bf95efaea4452975aea144a764402
52,ncgc326,noninhibitory chaperones,is a type of,ba3bf95efaea4452975aea144a764402
53,panobinostat,proteostasis regulators,is a type of,ba3bf95efaea4452975aea144a764402
54,trans-isrib,proteostasis regulators,is a type of,ba3bf95efaea4452975aea144a764402
55,pladienolide b,proteostasis regulators,is a type of,ba3bf95efaea4452975aea144a764402
56,lysofix-gba,fluorescence-quenched substrates,captures,ba3bf95efaea4452975aea144a764402
57,gcase activity,functional lysosomal activity,is measured by,ba3bf95efaea4452975aea144a764402
58,hgcase-1/23,monoclonal antibody,is used in,ba3bf95efaea4452975aea144a764402
59,immunofluorescence assay,gcase,visualizes,ba3bf95efaea4452975aea144a764402
60,lysosomal translocation,compound ncgc326,is associated with,c9c51ec400c44aafaed1197affee365f
61,compound ncgc326,glucosylsphingosine accumulation,reverses,c9c51ec400c44aafaed1197affee365f
62,combination therapy,synergistic effects,demonstrates,c9c51ec400c44aafaed1197affee365f
63,compound ncgc326,proteostasis regulators,enhances levels of,c9c51ec400c44aafaed1197affee365f
64,gcase-l444p variant,protein levels,are enhanced by,c9c51ec400c44aafaed1197affee365f
65,physiologically relevant assays,molecular identification,facilitates,c9c51ec400c44aafaed1197affee365f
66,molecular identification,pharmacological validation,leads to,c9c51ec400c44aafaed1197affee365f
67,pharmacological validation,medicinal chemistry optimization,supports,c9c51ec400c44aafaed1197affee365f
68,small molecules,gcase enzyme,target,c9c51ec400c44aafaed1197affee365f
69,gcase enzyme,compound ncgc326,is targeted by,c9c51ec400c44aafaed1197affee365f
70,experimental techniques,characterization methods,Experimental techniques are used to characterize materials.,7370cfe963604e849c06694ce7e14e02
71,data analysis,statistical methods,Data analysis often employs statistical methods to interpret results.,7370cfe963604e849c06694ce7e14e02
72,synthesis methods,material properties,Synthesis methods influence the properties of the resulting materials.,7370cfe963604e849c06694ce7e14e02
73,thermal analysis,phase transitions,Thermal analysis techniques are used to study phase transitions in materials.,7370cfe963604e849c06694ce7e14e02
74,mechanical testing,material strength,Mechanical testing assesses the strength of materials.,7370cfe963604e849c06694ce7e14e02
75,therapeutic intervention,gaucher disease (gd),is a viable treatment for,c8ae4087001a40bca706eba9227868b2
76,therapeutic intervention,parkinson's disease (pd),is a viable treatment for,c8ae4087001a40bca706eba9227868b2
77,gaucher disease (gd),parkinson's disease (pd),are conditions addressed by,c8ae4087001a40bca706eba9227868b2
78,gaucher disease (gd),therapeutic intervention,is developed for,c8ae4087001a40bca706eba9227868b2
79,parkinson's disease (pd),therapeutic intervention,is developed for,c8ae4087001a40bca706eba9227868b2
80,viability,therapeutic intervention,describes the quality of,c8ae4087001a40bca706eba9227868b2
81,therapeutic intervention,treatment,is a type of,c8ae4087001a40bca706eba9227868b2
82,gaucher disease (gd),treatment,requires a,c8ae4087001a40bca706eba9227868b2
83,parkinson's disease (pd),treatment,requires a,c8ae4087001a40bca706eba9227868b2
84,therapeutic intervention,development process,is part of the process of,c8ae4087001a40bca706eba9227868b2
85,hibit-gba1-wt protein,droplet digital pcr (ddpcr) method,was identified via,6c2a68ae4c1242c5a213a2676c65637d
86,hibit-gba1-wt protein,experimental procedures,was used for,6c2a68ae4c1242c5a213a2676c65637d
87,droplet digital pcr (ddpcr) method,hibit-gba1-wt protein,identifies,6c2a68ae4c1242c5a213a2676c65637d
88,experimental procedures,hibit-gba1-wt protein,involves,6c2a68ae4c1242c5a213a2676c65637d
89,hibit reporter,11-amino acid peptide tag,is a type of,f50ebb05e4b24517bf3cf4f176ae098b
90,hibit reporter,luminescence-based high-throughput screening (qhts),is suitable for,f50ebb05e4b24517bf3cf4f176ae098b
91,human glucocerebrosidase (gcase),hibit,is tagged with,f50ebb05e4b24517bf3cf4f176ae098b
92,n-terminal region,hibit,is location of,f50ebb05e4b24517bf3cf4f176ae098b
93,transgene,gba1 signal peptide,contains,f50ebb05e4b24517bf3cf4f176ae098b
94,transgene,hibit peptide tag,contains,f50ebb05e4b24517bf3cf4f176ae098b
95,transgene,glycine/serine linker,contains upstream of,f50ebb05e4b24517bf3cf4f176ae098b
96,gba1,transgene,is expressed from,f50ebb05e4b24517bf3cf4f176ae098b
97,gba1 knockout h4,human neuroglioma cell line,is a type of,f50ebb05e4b24517bf3cf4f176ae098b
98,reporter protein,localization,is subject to,f50ebb05e4b24517bf3cf4f176ae098b
99,results,findings,Results are often referred to as findings in the context of materials science research.,f27800fba4884822a6f007f16011a77f
100,monoclonal human gcase antibody,hgcase-1/23,is a type of,552c921bbe58430bba62fc716149ea1b
101,hibit-tagged gcase,lysosomal localization,shows,552c921bbe58430bba62fc716149ea1b
102,hibit-tagged gcase,endogenous gcase,is comparable to,552c921bbe58430bba62fc716149ea1b
103,hibit tag,gcase trafficking,does not interfere with,552c921bbe58430bba62fc716149ea1b
104,untagged gcase,endoplasmic reticulum accumulation,leads to,552c921bbe58430bba62fc716149ea1b
105,gcase trafficking,overexpression,is perturbed by,552c921bbe58430bba62fc716149ea1b
106,hibit-tagged gcase expression,gcase trafficking,addresses,552c921bbe58430bba62fc716149ea1b
107,gcase,lysosomal localization,is associated with,552c921bbe58430bba62fc716149ea1b
108,moderate expression,hibit-tagged gcase,results in,552c921bbe58430bba62fc716149ea1b
109,high levels of untagged gcase,clear lysosomal localization,indicates lack of,552c921bbe58430bba62fc716149ea1b
110,transgene cassette,citrate lyase beta-like (clybl) gene,is integrated into,30743621907743c18a3ac935f6b15c79
111,transcription activator-like effector nucleases (talens),transgene cassette,is used to integrate,30743621907743c18a3ac935f6b15c79
112,gba1 knockout h4 cell line,transgene cassette,receives integration of,30743621907743c18a3ac935f6b15c79
113,integrative gene transfer method,transgene,allows efficient knock-in of,30743621907743c18a3ac935f6b15c79
114,cag promoter,transgene,drives sustained expression of,30743621907743c18a3ac935f6b15c79
115,gba1 knockout h4 clone,single copy,contains,30743621907743c18a3ac935f6b15c79
116,transgene,local gene expression,has minimal impact on,30743621907743c18a3ac935f6b15c79
117,transgene,global gene expression,has minimal impact on,30743621907743c18a3ac935f6b15c79
118,intron,citrate lyase beta-like (clybl) gene,is a location within,30743621907743c18a3ac935f6b15c79
119,transcription activator-like effector nucleases (talens),gene editing,is a method of,30743621907743c18a3ac935f6b15c79
120,materials science,nanomaterials,Nanomaterials are a subfield of materials science focusing on materials with structures at the nanoscale.,d9a068b1fde144b8be1d9ae12c164f0a
121,materials science,metallurgy,Metallurgy is a branch of materials science that deals with the physical and chemical behavior of metallic elements.,d9a068b1fde144b8be1d9ae12c164f0a
122,materials science,polymer science,Polymer science is a field within materials science that studies the properties and applications of polymers.,d9a068b1fde144b8be1d9ae12c164f0a
123,materials science,ceramics,"Ceramics are a category of materials studied within materials science, focusing on inorganic, non-metallic solids.",d9a068b1fde144b8be1d9ae12c164f0a
124,materials science,composite materials,Composite materials are made from two or more constituent materials with significantly different physical or chemical properties.,d9a068b1fde144b8be1d9ae12c164f0a
125,hibit peptide reporter tag,gcase variants,preserves trafficking and function of,1c5675f4fb034241aaeb0e95567374fd
126,hibit-gcase h4 cell lines,ultrahigh-throughput screening format,tested in,1c5675f4fb034241aaeb0e95567374fd
127,ultrahigh-throughput screening format,"1,536-well plate",is a type of,1c5675f4fb034241aaeb0e95567374fd
128,hibit-gcase-l444p variant,dose-dependent response,shows,1c5675f4fb034241aaeb0e95567374fd
129,primary screening assay,716 compounds,identified,1c5675f4fb034241aaeb0e95567374fd
130,716 compounds,hit compounds,represents,1c5675f4fb034241aaeb0e95567374fd
131,hit compounds,140 confirmed hits,includes,1c5675f4fb034241aaeb0e95567374fd
132,final hit compounds,mechanisms of action,represented several,1c5675f4fb034241aaeb0e95567374fd
133,final hit compounds,epigenetic mechanisms,includes,1c5675f4fb034241aaeb0e95567374fd
134,cell-based assay platform,quantitative high-throughput screening (qhts),provides,1c5675f4fb034241aaeb0e95567374fd
135,biological modulators,proteasome inhibitors,are types of,d8bea43d8e874d7089c5b3ce753e7125
136,biological modulators,gsk-3 inhibitors,are types of,d8bea43d8e874d7089c5b3ce753e7125
137,pladienolide b,potent compounds,is a type of,d8bea43d8e874d7089c5b3ce753e7125
138,trans-isrib,potent compounds,is a type of,d8bea43d8e874d7089c5b3ce753e7125
139,pladienolide b,gsk-3 inhibitors,is a specific example of,d8bea43d8e874d7089c5b3ce753e7125
140,trans-isrib,proteasome inhibitors,is a specific example of,d8bea43d8e874d7089c5b3ce753e7125
141,proteasome inhibitors,therapeutic applications,are used in,d8bea43d8e874d7089c5b3ce753e7125
142,gsk-3 inhibitors,therapeutic applications,are used in,d8bea43d8e874d7089c5b3ce753e7125
143,potent compounds,screening methods,are identified by,d8bea43d8e874d7089c5b3ce753e7125
144,biological modulators,cellular regulation,are involved in,d8bea43d8e874d7089c5b3ce753e7125
145,materials science,conclusion,The conclusion summarizes findings and implications derived from research in materials science.,c2e70deee6c2442cb169e8dcb53c2a61
146,small-molecule gcase enhancers,cell-based assays,is a challenge for,92745fc73fe94b628d4d8ad3859e2297
147,cell-based assays,high-throughput screening (hts),is amenable to,92745fc73fe94b628d4d8ad3859e2297
148,high-throughput screening (hts),compound identification,drives,92745fc73fe94b628d4d8ad3859e2297
149,compound identification,pharmacological validation,is followed by,92745fc73fe94b628d4d8ad3859e2297
150,pharmacological validation,medicinal chemistry optimization,is part of,92745fc73fe94b628d4d8ad3859e2297
151,novel chemical entities,gcase enhancers,is a type of,92745fc73fe94b628d4d8ad3859e2297
152,gba1 molecular target,scientific knowledge,informs the design of,92745fc73fe94b628d4d8ad3859e2297
153,gcase enhancers,therapeutic agents,is a type of,92745fc73fe94b628d4d8ad3859e2297
154,integrated approach,rational drug development,enables,92745fc73fe94b628d4d8ad3859e2297
155,physiologically relevant,gcase enhancers,is a characteristic of,92745fc73fe94b628d4d8ad3859e2297
156,translational assays,drug discovery,accelerate,58ba000eb1f74acbaf3fb5b74133f5f8
157,n-terminal hibit tag,gcase maturation,has negligible influence on,58ba000eb1f74acbaf3fb5b74133f5f8
158,n-terminal hibit tag,gcase trafficking,has negligible influence on,58ba000eb1f74acbaf3fb5b74133f5f8
159,n-terminal hibit tag,gcase function,has negligible influence on,58ba000eb1f74acbaf3fb5b74133f5f8
160,hibit-gcase-l444p assay,protein complexes (pcs),detects,58ba000eb1f74acbaf3fb5b74133f5f8
161,hibit-gcase-l444p assay,protein residues (prs),detects,58ba000eb1f74acbaf3fb5b74133f5f8
162,hibit-gcase-l444p assay,lead discovery,utility for,58ba000eb1f74acbaf3fb5b74133f5f8
163,hibit-gcase-l444p assay,drug development,utility for,58ba000eb1f74acbaf3fb5b74133f5f8
164,gcase maturation,gcase trafficking,affects,58ba000eb1f74acbaf3fb5b74133f5f8
165,gcase maturation,gcase function,affects,58ba000eb1f74acbaf3fb5b74133f5f8
166,gba1 gene,gaucher disease (gd),is a target for,bf3a1236649540429951c4a914dbbb3f
167,gba1 gene,gba1-related parkinson's disease (gba1-pd),is related to,bf3a1236649540429951c4a914dbbb3f
168,drug discovery pipeline,multilevel approach,is a type of,bf3a1236649540429951c4a914dbbb3f
169,small molecules,gcase-l444p variant,increase levels of,bf3a1236649540429951c4a914dbbb3f
170,lysosomal activity,lysosomal translocation,is associated with,bf3a1236649540429951c4a914dbbb3f
171,pladienolide b,mechanism of action,has a novel,bf3a1236649540429951c4a914dbbb3f
172,ncgc326,pharmacological compound (pc),is an improved derivative of,bf3a1236649540429951c4a914dbbb3f
173,glucer accumulation,h4 cell model,is reversed in,bf3a1236649540429951c4a914dbbb3f
174,gcase-l444p variant,protein levels,affects,bf3a1236649540429951c4a914dbbb3f
175,lysosomal activity,small molecules,is enhanced by,bf3a1236649540429951c4a914dbbb3f
176,combinatorial matrix screening,synergistic interactions,is a method to identify,2772668019984017a983a48b60d06f93
177,pharmacological agents,combinations,interact synergistically with,2772668019984017a983a48b60d06f93
178,gcase-l444p variant,enzyme levels,enhanced by,2772668019984017a983a48b60d06f93
179,screening hits,validation assays,validated in,2772668019984017a983a48b60d06f93
180,therapeutic intervention,patients,provides for,2772668019984017a983a48b60d06f93
181,neuronopathic gaucher disease,gba1-related parkinson's disease,is a disease associated with,2772668019984017a983a48b60d06f93
182,gcase activity deficiencies,related diseases,associated with,2772668019984017a983a48b60d06f93
183,screening hits,subsequent investigation,should be prioritized for,2772668019984017a983a48b60d06f93
184,therapeutic intervention,efficacy,is a characteristic of,2772668019984017a983a48b60d06f93
185,gcase-l444p variant,synergistic interactions,involves,2772668019984017a983a48b60d06f93
